注射用舒巴坦钠/注射用度洛巴坦钠组合包装 | China Drugs ListSulbactam sodium for injection / durlobactam sodium for injection co-pack | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- EntasisTherapeutics Inc.Entasis Therapeutics Inc.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 感染性疾病Infectious diseases
- 公开来源记录的适应症
- 本品用于治疗 18岁及以上患者由鲍曼-醋酸钙不动杆菌复合体敏感分离株所致医院获得性细菌性肺炎（HABP）、呼吸机相关性细菌性肺炎（VABP）。本品不适用于治疗鲍曼- 醋酸钙不动杆菌复合体敏感分离株以外病原体所致HABP/VABP（见【临床试验】）。为减少耐药菌形成，维持本品和其它抗菌药物的有效性，本品仅用于治疗已证实或强烈疑似由敏感细菌引起的感染。当可获得培养及药敏信息，选择或调整抗菌治疗时应予以考虑。如缺少此类数据，根据经验进行治疗选择时可参考当地流行病学和药敏性特征信息。Treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in patients aged 18 years or older caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex. It is not indicated for HABP/VABP caused by pathogens other than susceptible isolates of this complex (see Clinical Studies in the prescribing information). To reduce development of resistant bacteria and maintain antibacterial effectiveness, use only for infections proven or strongly suspected to be caused by susceptible bacteria. Consider available culture and susceptibility results when selecting or adjusting therapy. When these data are unavailable, local epidemiology and susceptibility patterns may guide empiric treatment.
- 适应症来源与口径
- 来源日期： 2024, 2026. 适应症反映所引用的历史批准范围，不是截至2026年的完整适应症。Source date(s): 2024, 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
- 说明书信息局限
- 已取得完整官方药品说明书。 现有完整说明书来自海外辖区；尚未取得完整的中国现行说明书。中国适应症另由中国来源支持。Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.